Metabolic Health
GLP-1 receptor agonists and dual/triple incretin receptor agonists studied for metabolic regulation, appetite signalling, and body composition research — including next-generation compounds such as Retatrutide, Tirzepatide, and Semaglutide analogues.
Jastreboff, A.M. et al. (2023) demonstrated that Retatrutide (GGG tri-agonist) produced up to 24.2% body weight reduction over 48 weeks in phase 2 trials — N Engl J Med, 389, 514-526. [View Publication]
HGH Fragment 176-191
Strength
Lipolytic HGH fragment studied for fat metabolism without IGF-1 elevation.
For research purposes only
The UltiFstack
Strength
Advanced tri-peptide blend targeting fat metabolism, GH axis stimulation, and mitochondrial energy regulation.
For research purposes only
AOD9604
Strength
hGH fragment studied for fat metabolism without insulin resistance.
For research purposes only
Tesamorelin
Strength
GHRH analogue investigated for visceral fat reduction and GH axis research.
For research purposes only
Tirzepatide
Strength
Dual GIP/GLP-1 agonist showing superior weight reduction in clinical models.
For research purposes only
Retatrutide
Strength
Triple receptor agonist with the highest weight reduction reported in phase 2 trials.
For research purposes only
Semaglutide
Strength
GLP-1 receptor agonist studied for metabolic regulation and appetite control.
For research purposes only